Evofem Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. A pre-recorded fireside chat featuring CEO Saundra Pelletier will be available on November 23 at 10:00 AM Eastern Time. The chat can be accessed on the company's website under the Events and Presentations section. Evofem focuses on women's sexual and reproductive health, with its product, Phexxi®, being the first hormone-free vaginal gel approved in the U.S. for pregnancy prevention.

SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3, 2020.

In advance of the virtual conference and investor meetings, a pre-recorded fireside chat with Saundra Pelletier, CEO of Evofem Biosciences, will be made available on Monday, November 23 at 10:00 AM Eastern Time.  Interested parties may access the fireside chat by visiting the

Investors section of the Evofem Biosciences website at www.evofem.com, under the Events and Presentations tab. 

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

Media Contact
Ellen Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-piper-sandler-32nd-annual-virtual-healthcare-conference-301178010.html

SOURCE Evofem Biosciences, Inc.

FAQ

When is Evofem Biosciences participating in the Piper Sandler conference?

Evofem Biosciences will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020.

What can investors expect from Evofem's fireside chat?

A pre-recorded fireside chat with CEO Saundra Pelletier will be available on November 23 at 10:00 AM Eastern Time.

How can I access the fireside chat for Evofem Biosciences?

Interested parties can access the fireside chat on Evofem's website under the Events and Presentations section.

What is Phexxi® by Evofem Biosciences?

Phexxi® is the first hormone-free, prescription vaginal gel approved in the U.S. for the prevention of pregnancy.

What is the focus of Evofem Biosciences?

Evofem Biosciences is committed to developing innovative products for women's sexual and reproductive health, including contraception and STI protection.